Trump Announces Two‑Stage 200 Percent Tariff on Indian Generic Drugs, Threatening $9.7 Billion Export Market

Trump announced a two‑stage tariff on imported generic medicines, with a 0 percent rate beginning 1 August 2026 and a 200 percent rate kicking in two years later, targeting Indian exporters and applying to all generic drug categories.

Indian Pharma industry estimates the tariff could jeopardize roughly $9.7 billion of annual generic drug sales to the United States, a market that currently supports a large share of its export earnings.

US Consumers may face higher prescription costs as the steep tariff is expected to be passed on, prompting criticism from Indian trade groups that the measure is “not practical” and could hurt affordable drug access.

Market reaction saw pharma stocks tumble after the announcement, with analysts warning that the tariff timeline adds uncertainty to supply chains and could trigger broader trade tensions between Washington and New Delhi.